Glaxo shrugs off lower Zantac sales
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Glaxo Wellcome shares shrugged off an annual meeting trading statement pointing to a 5 per cent decline in sales of Zantac, its best-selling ulcer treatment.
Analysts said the downturn was in line with expectations. Underlying growth of the combined company's other treatments was 8 per cent in the 10 months to October, according to Sir Colin Corness, chairman, who added that the integration with Wellcome was on track around the world.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments